[Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487].

Abstract

A rabbit VX2 colon cancer model with spontaneous liver metastases was used to evaluate the antitumor effect of an angiogenesis inhibitor, FR-118487. FR-118487 (1 mg/kg/day) was infused continuously into the portal vein for a week after resection of primary colon cancer lesions (FR group). The incidence of liver metastases was 71.4% (5/7) in FR group, and 100% (7/7) in control group. The number and the weight of liver metastatic nodules were 31.0 +/0 36.0 and 1.4 +/- 1.8 g in FR group versus 83.7 +/- 73.9 and 6.5 +/- 4.9 g in control group, respectively. The metastases in FR group were significantly decreased in weight compared with those in control group (p < 0.05). No anastomotic leakage was recognized in either group. No side effects of FR-118487 such as body weight loss were found. Continuous intraportal infusion of FR-118487 in the early postoperative period may be effective to suppress liver metastases from colon cancer by inhibiting the angiogenesis concerning liver metastases.

• Authors: I Eda, H Soga, M Ueoka, K Yamashita, S Kawasaki, H Doihara, R Hirai, N Shimizu
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 22 Issue 11 Pg. 1480-2 (Sep 1995) ISSN: 0385-0684 [Print] Japan
• PMID: 7574737 (Publication Type: English Abstract, Journal Article)

Chemical References

• FR 118487
• Spiro Compounds

Topics

• Animals
• Colonic Neoplasms (pathology)
• Infusion Pumps, Implantable
• Liver Neoplasms (blood supply, secondary)
• Neovascularization, Pathologic (prevention & control)
• Portal Vein
• Postoperative Period
• Rabbits
• Spiro Compounds (therapeutic use)